<DOC>
	<DOCNO>NCT01689051</DOCNO>
	<brief_summary>Diabetes high blood pressure risk factor develop heart disease . An increase number diabetes patient expect . This increase number patient heart disease , since vast majority diabetes die heart disease , extremely important investigate disease prevent treat . Studies animal show intestinal hormone glucagon-like peptide-1 ( GLP-1 ) expand blood vessel , thus lower blood pressure , know whether effect find human , investigate . Studies also show GLP-1 lower blood sugar , unclear whether solely due increase insulin production , weight loss associate GLP-1 intake GLP-1 effect muscle increase uptake sugar . We investigate whether GLP-1 enhances absorption sugar leg . The investigator also examine whether effect great people diabetes healthy .</brief_summary>
	<brief_title>Vasodilatory Metabolic Effects Glucagon-like Peptide-1 Periphery Circulation Patients With Without Type 2 Diabetes Mellitus</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Glucagon</mesh_term>
	<mesh_term>Glucagon-Like Peptide 1</mesh_term>
	<criteria>Written inform consent T2DM accord WHO 's criterion ( T2DM subject ) Anemia T1DM Severe liver renal disease Severe heart disease Atrial fibrillation</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>Type 2 diabetes</keyword>
	<keyword>Blod pressure</keyword>
	<keyword>Glucagon-like peptide-1</keyword>
	<keyword>Human physiology</keyword>
	<keyword>Blood flow</keyword>
</DOC>